


# DAY 03 | Wednesday, August 24

## Health Industry

2022 Cooperation Forum on  
Science, Technology and Innovation  
**BRAZIL & CHINA**  
INDUSTRIAL INNOVATION



### David Livingstone Alves Figueiredo,

**Professor of the Department of Medicine at Unicentro and President of IPEC-Institute for Cancer Research**

David Livingstone A Figueiredo, MD, PhD. Head and Neck surgeon. Professor and Chief of the Medical Department – Unicentro. President of Institute for Cancer Research. Coordinator of NAPI Genomics (new arrangement of Research and innovation).



### Binglai Chen,

**Guangdong Province President of Guangdong Sturms Health Technology Co.**

(2019-). CEO of Shanghai Houchao Biotechnology Co., Ltd. (2011-). Founding Expert, Stem Cell Translational Medicine Center, Shanghai Oriental Hospital of Tongji University (2012-2014). Visiting Professor, Zhongshan Hospital of Fudan University (2012-2017). Postdoctoral Fellow, University of Bologna, Italy (2005-2007). Postdoctoral Fellow, Mount Sinai School of Medicine, New York University, USA (2007-2010). PhD of Central South University (2000-2003). Resident Physician of the Department of Obstetrics and Gynecology, Xiangya Hospital of Central South University (1990-2000).



### Valdir Gomes,

**Business Development Manager of Advanced Health Systems Institute (ISI-SAS) - CIMATEC Health**

I have a Bachelor's Degree in International Relations and a postgraduate course in Legislative Process/Public Policy. In addition, I have a Master's Degree in Management and Industrial Technology and I am currently doing a PhD in the same program. In my 15 years of experience in the health sector, I have worked in hospitals, at the State of Bahia Secretariat of Health and at the Department of the Industrial Health Complex of the Ministry of Health. Currently, I am the Business Manager in ISI (SENAI Institute of Innovation) of Advanced Health Systems - SENAI CIMATEC. I am in charge of the institutional articulation and I have worked in the prospection of strategic partnerships with governmental agencies, international organizations, research centers and private companies from CEIS (Brazilian Industrial Health Complex) including the pharmaceutical companies and the medical device companies.



### Shelley He,

**Senior Vice President of Techpool Bio-Pharma Co. Ltd.**

Shelley joined Techpool in February 2011, currently appointed as Vice General Manager, Head of Innovation Business, responsible for new product launch, international business and in vitro diagnostics unit. Prior to the current position, Shelley was CFO and board secretary, in charge of finance, ISIT, legal, procurement, distribution and channel management. Shelley has over 20 years' experience in sales management, financial management, ISIT, legal, compliance, procurement and human resources management across a variety of industries such as pharmaceutical, market research, retailing and manufacturing, and has made great achievement.



### Jing Yang,

**Researcher of the National Center for Protein Science · Beijing**

His research group is interested in advancing chemical proteomic technologies to answer fundamental questions in redox biology and to explore the “druggable” space of the cysteine redox proteome. An overarching goal is to understand the chemistry and molecular mechanisms of cysteine-mediated cellular regulation and signal transduction, with particular emphasis on the role of cysteine redox transformation, a ubiquitous and conserved mechanism for controlling protein function. They have developed several “clickable” probes for chemoselective labeling of many distinct types of cysteine redox forms (e.g., SH, -SOH, SO<sub>2</sub>H, and -SSH). In combination with state-of-the-art chemoproteomics, these probes greatly expand the landscape of the cysteine redoxome in various cell lines and model organisms, as well as the substrate spectrum of many functionally important enzymatic reducing systems, including thioredoxin/thioredoxin reductase and sulfiredoxin. These analyses therefore not only generate many great resources for the field of redox biology, but also provides a great opportunity to study cysteine-mediated redox networks in a range of biological processes and adaptive responses in physiology and pathophysiology. Projecting forward, the ultimate goal of my research is to accelerate the discovery of key regulatory nodes of redox signaling networks, profile changes in functionally important cysteines associated with disease, and harness this information for the development of new therapeutic strategies.